103 results about "Macrogol" patented technology

The invention belongs to the technical field of bionic nano-drugs, and particularly relates to a bionic vesicle preparation as well as a preparation method and application thereof. The bionic vesicle preparation disclosed by the invention is prepared from the following raw materials: mesenchymal stem cell outer vesicles, nintedanib and DSPE-PEG-HA (hyaluronic acid modified pegylated phospholipid); the nintedanib is loaded in the mesenchymal stem cell outer vesicle, and the DSPE-PEG-HA is coupled to the surface of the mesenchymal stem cell outer vesicle. The bionic vesicle preparation disclosed by the invention can be used for directly delivering a drug to a pulmonary fibrosis injury part through inhalation type drug delivery, and acting on a focus part at a higher local concentration, meanwhile, the exposure of the drug in whole-body circulation is remarkably reduced, the occurrence of side effects is reduced, and the specific targeting intervention and regulation on fibroblasts are realized.

Provided herein are PEGylated liposomes, and methods of making and using thereof. The PEGylated liposomes comprise at least a cholesterol, a non-PEGylated neutral lipid, and a PEGylated lipid, wherein the average molecular weight of the PEG component in the PEGylated lipid is about 5000 Daltons or less. The PEGylated liposomes are stable and capable of delivery of an agent for the generation of an immune response, for example an agent for vaccine, therapeutic, or diagnostic uses. Compositions and methods related to making the PEGylated liposomes and using the PEGylated liposomes for stimulating an immune response are also provided.

Biomaterials disclosed herein can comprise a hydrogel comprising PEG, gelatin, and a glycosaminoglycan with sulfated moiety; and chondrogenic, osteogenic, and immunomodulatory cytokines; wherein the biomaterial is capable of potentiating bone regeneration in a compromised wound while reducing inflammatory response. The glycosaminoglycan with sulfated moiety can comprise heparin, heparan sulfate, keratin sulfate, chondroitin sulfate, dermatan sulfate, and / or similar materials. The biomaterial can further comprise mesenchymal stem cells (MSCs), a crosslinking initiator, microparticles and nanoparticles, and or other materials. The biomaterial can be injectable into a wound, or the biomaterial can be loaded in, or further comprise a porous scaffold providing mechanical support for other components of the biomaterial, such that it can be implanted into a wound.

The invention discloses allicin oleogel as well as a preparation method and application thereof, and belongs to the technical field of medicines. The allicin oleogel is prepared from the following raw materials: allicin, an oil phase, a gelator and a surfactant, the gelator comprises beeswax and / or fruit wax; the surfactant comprises one or more of caprylic / capric polyethylene glycol glyceride, Tween 20 and polyglycerol fatty acid ester. The gel factor forms oil gel through crystal self-assembly, allicin is solidified and intercepted in the oil gel, the gel factor is optimized, and a surfactant is used in a matched manner, so that a release behavior similar to that of a mixed solution of free allicin and an oil phase can be obtained, and the transdermal release rate is improved. The allicin oil gel can effectively entrap allicin, cover the peculiar smell of the allicin and improve the stability of the allicin, and through abdominal transdermal administration, the medicine accumulation amount in subcutaneous adipose tissues is remarkably increased, and the treatment effect on obesity and complications thereof can be improved.

Provided herein are PEGylated liposomes, and methods of making and using thereof. The PEGylated liposomes comprise at least a cholesterol, a non-PEGylated neutral lipid, and a PEGylated lipid, wherein the average molecular weight of the PEG component in the PEGylated lipid is about 5000 Daltons or less. The PEGylated liposomes are stable and capable of delivery of an agent for the generation of an immune response, for example an agent for vaccine, therapeutic, or diagnostic uses. Compositions and methods related to making the PEGylated liposomes and using the PEGylated liposomes for stimulating an immune response are also provided.

The invention discloses application of adenosine deaminase or a modifier thereof in preparation of a medicine for treating diabetic nephropathy. After intraperitoneal injection treatment of polyethylene glycol modified escherichia coli expressed mouse adenosine deaminase is carried out on a mouse with diabetic nephropathy, the damage degree of the kidney of the mouse is obviously weakened. According to the invention, the adenosine deaminase or the modifier thereof has an obvious treatment effect on the type 2 diabetic nephropathy for the first time, and the adenosine deaminase and the modifier thereof have potential application prospects in preparation of the medicines for treating the type 2 diabetic nephropathy.

The invention discloses an application of pegylated irinotecan in preparation of a medicine for preventing and / or treating triple-negative breast cancer brain metastasis diseases, which is shown by in-vivo imaging observation and lifetime observation of high, medium and low dose groups of pegylated irinotecan with a specific structure. The high-dose group, the medium-dose group and the low-dose group all have a definite anti-tumor effect, bioluminescence signal values are inhibited to different degrees, the lifetime is prolonged, and the lifetime of the high-dose group and the lifetime of the medium-dose group are remarkably longer than that of the NKTR-102 group.

The invention discloses a vitamin D3-polyethylene glycol composition and a preparation method thereof, the vitamin D3-polyethylene glycol composition comprises vitamin D3, a dispersion medium, an adsorbent and polyethylene glycol, the vitamin D3 is dissolved in the dispersion medium, the adsorbent is used for adsorption, and then the mixture is added into hot-melt polyethylene glycol for dispersion to obtain the vitamin D3-polyethylene glycol composition. The dosage of the polyethylene glycol is controlled to be 70%-90% of that of the vitamin D3-polyethylene glycol composition; the vitamin D3 in the calcium carbonate / vitamin D3 pharmaceutical composition prepared by the invention has excellent long-term stability, and also has good mixing uniformity and content uniformity; the preparation process is simple, the vitamin D3 and other auxiliary materials do not need to be prepared into large particles in advance, the particles are easy to transfer without freeze-drying, the material loss is less, and the preparation method is suitable for industrialization.

The invention relates to a rapid setting liquid lung sealant that forms a highly adherent and elastic hydrogel. Provided are lung sealants comprising two high molecular weight (20 kDa) multi-arm PEG compositions wherein the first PEG composition includes an alkaline buffer and the second PEG composition includes a mildly acidic buffer for optimized set up time and extended working time. In some embodiments, the PEGs further comprise a radioprotectant such as tocopherol. In some embodiments, a colorant is added to one or both PEGs of the lung sealant to improve visualization of the lung sealant against human lung tissue.

The present invention relates to compressed hemostatic tablets or forms comprising a fibrous nonwoven oxidized cellulose (OC or ORC) multilayer material compressed into a shape-stable tablet, further comprising a calcium salt, and capable of rapidly expanding upon contact with blood or plasma. The compressed forms may further comprise multi-arm PEG-SG and are dimensionally stable, preferably in terms of length and width, for at least 48 hours after compression. In some embodiments, upon contact with blood, the compressed forms expand to 1.5 to 5 times their tablet length in 5 seconds, to 2 to 6 times their tablet length in 20 seconds, and to 3 to 6 times their tablet length in 5 minutes. The compressed forms are effective for hemostasis in heparinized blood.

The invention relates to a process for obtaining a milk extracellular vesicle (EV)- enriched product from whey by mixing whey with a PEG solution providing a whey- PEG mixture; and centrifuging the whey-PEG mixture providing a pellet enriched in milk EV.

Disclosed herein are methods of administering compositions comprising a mixture of salts that induce purgation of the colon and are useful to cleanse the colon. Furthermore, the disclosed methods prevent degradation of PEG and allow for cleansing of the colon without the use of adjunct laxatives, including stimulant laxatives such as bisacodyl. The disclosed methods are superior to the prior art in that they allow for higher tolerability, improved safety, lower volumes, and improved patient compliance.

Nanoemulsion composition for the treatment of inflammatory bowel diseases, comprising: a) 1.0% (w / w) curcumin as active pharmaceutical ingredient; b) 10.0% w / w Caprylic / Capric triglycerides as oil phase; c) 15.0% w / w Tween 80 as surfactant; d) 10.0% w / w PEG 400 as co-surfactant; e) 2.0% w / w lecithin as emulsifier; f) 2.0% w / w ethanol as a solubilizer; and g) distilled water qs to 100 w / w, h) wherein the composition forms a nanoemulsion having a mean particle size in the range of 90-120 nm and a polydispersity index of less than 0.3 and provides sustained curcumin release for at least 12 hours in simulated intestinal fluid.

Provided herein are PEGylated liposomes, and methods of making and using thereof. The PEGylated liposomes comprise DSPE-peg2000 and nosiheptide in a molar ratio of 3:1. Compositions and methods which is related to making the PEGylated liposomes and using the PEGylated liposomes for preventing or treating bacterial infection are also provided.

This invention relates to polymer drug conjugates according to formula I, and their use for treatment of diseases such as cancer.

The present invention concerns methods comprising co-administration of pegfilgrastim and romiplostim for treatment of diseases and conditions characterized by low neutrophil levels (neutropenia) and / or low platelet levels (thrombocytopenia). The present invention concerns an enhanced effect on neutrophil levels and on platelet levels resulting from co-administration of pegfilgrastim and romiplostim. The present invention further concerns a method of treating a patient who has been exposed to radiation, which comprises administering romiplostim at a dose of about 1 to about 10 g / kg. The invention further concerns such methods wherein a single dose of romiplostim is administered to the patient and wherein romiplostim is administered about 24 hours or less after the radiation exposure. The invention further concerns treatment with romiplostim and pegfilgrastim for radiation exposure. Such methods relate to treatment of acute radiation syndrome and treatment to counteract the effects of radiation therapy and other sources of radiation exposure.

The invention discloses an application of gelatinized intestinal epithelial cells in preparation of drugs for treating inflammatory bowel disease, the gelatinized intestinal epithelial cells take mouse intestinal epithelial cells as cores, poly (ethylene glycol) diacrylate, a photoinitiator and poly-L-lysine permeate into the cells through low-temperature freeze thawing, and an intracellular porous hydrogel skeleton is formed through ultraviolet crosslinking. The gelated intestinal epithelial cell has a strong cfDNA and inflammatory factor removal function, has good biocompatibility, has no direct or indirect toxic effect on a human body, has no potential toxicity, and can be used for treating inflammatory bowel diseases.

The present invention relates to a pegylated GDF5 protein and uses thereof.

The invention belongs to the technical field of biological medicine, and relates to a releasable pegylated sirolimus compound and application thereof. The invention provides a releasable PEGylated sirolimus compound. The compound can be self-assembled to form micelles, prepared into nanoparticles and targeted to immune cells, regulates the release behavior of drugs, reduces the system toxicity and prolongs the biological half-life period. And moreover, the sirolimus-hydrophilic PEG conjugate has a proper hydrophobic sirolimus end and a hydrophilic PEG chain end, can effectively release drugs in immune cells, and is a good carrier for preparing nanoparticles. The invention provides a releasable PEGylated sirolimus compound, a nano-drug and a pharmaceutical composition prepared from the releasable PEGylated sirolimus compound, and application of the releasable PEGylated sirolimus compound in preparation of drugs for reducing immune response.

Provided herein are methods for treating cancer comprising administering to a subject in need thereof an adamantane derivative, or a pharmaceutically acceptable salt thereof, such as rimantadine or amantadine. In some embodiments, the adamantane derivative is PEGylated.

Disclosed herein are methods of administering compositions comprising a mixture of salts that induce purgation of the colon and are useful to cleanse the colon. Furthermore, the disclosed methods prevent degradation of PEG and allow for cleansing of the colon without the use of adjunct laxatives, including stimulant laxatives such as bisacodyl. The disclosed methods are superior to the prior art in that they allow for higher tolerability, improved safety, lower volumes, and improved patient compliance.

Disclosed herein are methods of administering compositions comprising a mixture of salts that induce purgation of the colon and are useful to cleanse the colon. Furthermore, the disclosed methods prevent degradation of PEG and allow for cleansing of the colon without the use of adjunct laxatives, including stimulant laxatives such as bisacodyl. The disclosed methods are superior to the prior art in that they allow for higher tolerability, improved safety, lower volumes, and improved patient compliance.

The invention relates to a rapid setting liquid lung sealant that forms a highly adherent and elastic hydrogel. Provided are lung sealants comprising two high molecular weight (20 kDa) multi-arm PEG compositions wherein the first PEG composition includes an alkaline buffer and the second PEG composition includes a mildly acidic buffer for optimized set up time and extended working time. In some embodiments, the PEGs further comprise a radioprotectant such as tocopherol. In some embodiments, a colorant is added to one or both PEGs of the lung sealant to improve visualization of the lung sealant against human lung tissue.

A cleansing composition in a rinse-off formulation provides a stable disposition of an acne treatment active, for example, beta hydroxy acid, on the skin that is resistant to removal by rinsing with or without use of a cleansing apparatus. The cleansing composition includes at least one beta hydroxy present in an amount that is greater than 1%, by weight of the composition, and an aqueous carrier that includes lauryl lactate, at least one surfactant, at least one cationic agent, and optional additives. The cleansing composition has a pleasing high foam, is free of drying and irritating sulfates and PEG-type components, and demonstrates phase stability up to at least three months up to 45 °C, and retention of beta hydroxy acid active on the skin after cleansing and rinsing.

Provided are lyophilized formulations comprising pegylated arginine deiminase (ADI-PEG) and related reconstituted liquid compositions and methods of using the compositions for arginine depletion therapies, including for the treatment of various cancers.

In particular, the present disclosure provides pharmaceutical compositions of avacactide polyethylene glycol (avacactide pegol) that have sufficient purity and efficacy to be suitable for administration to human patients in the treatment of a variety of ocular disorders and diseases.

A method of treating Arginase 1 (ARG1) deficiency (ARG1-D) in a subject, comprising administering a pegzilarginase to the subject, wherein the pegzilarginase is a pegylated human arginase 1 comprising a cobalt metal cofactor, and wherein the pegzilarginase is administered weekly at a dose of from about 0.05 mg / kg to about 0.2 mg / kg.

The present invention provides stable pharmaceutical compositions of pegylated carfilzomib compounds, methods for preparing the compositions, and uses of the compositions for treating cancer, including hematologic malignancies such as multiple myeloma. The compositions can be stored in frozen form or lyophilized to dry solid form.